TPK Agonists for Restoring TDP in Alzheimer's Metabolic Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for Alzheimer's disease, particularly the use of a specific and effective solution for the prophylaxis or treatment of neurodegenerative diseases, such as Alzheimer's, are lacking due to unclear pathogenesis and the absence of effective drugs.
Innovation Solution
Administering a thiamine pyrophosphokinase (TPK) agonist to enhance thiamine diphosphate (TDP) levels, which are decreased in Alzheimer's patients, thereby addressing the underlying metabolic disorder of glucose metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for Alzheimer's disease are used, then current management can be maintained, but effective prophylaxis or treatment is lacking due to unclear pathogenesis
Solution Approach 1:
The patent identifies specific biochemical parameter changes (decreased TDP levels, impaired glucose metabolism) as markers for Alzheimer's disease and uses these parameters to guide therapeutic intervention with TPK agonists, thereby transforming the approach from generic treatment to targeted therapy based on measurable biochemical parameters
Solution Approach 2:
The patent introduces thiamine diphosphate (TDP) as an intermediary substance that plays a crucial role in glucose metabolism and neuronal function. By targeting TDP levels and using TPK agonists to restore TDP, the patent establishes a mechanistic bridge between metabolic dysfunction and neurodegeneration, enabling more effective treatment
2Reliability
If thiamine pyrophosphokinase (TPK) agonist is administered to increase TDP levels, then metabolic disorder can be addressed, but the complexity of drug development increases
Solution Approach 1:
The patent extracts and isolates the specific enzymatic defect (TPK inhibition) from the complex pathology of Alzheimer's disease. By focusing on this single vulnerable target and developing TPK agonists that specifically address this defect, the patent simplifies the treatment approach while maintaining high therapeutic effectiveness
Solution Approach 2:
The patent employs TPK agonists that work through the body's existing enzymatic systems. The agonists activate the natural TPK enzyme to restore TDP production, utilizing the body's own metabolic pathways rather than requiring external complex intervention systems, thereby reducing development complexity
3Reliability
If TPK agonist is used to treat Alzheimer's disease, then cognitive function may be improved, but the cost of treatment increases
Solution Approach 1:
The patent focuses on restoring specific biochemical parameters (TDP levels, glucose metabolism) that are depleted in Alzheimer's disease. By targeting these specific parameter changes rather than providing broad-spectrum treatment, the patent achieves cognitive improvement with more cost-effective, targeted therapy
Solution Approach 2:
The patent employs small-molecule TPK agonists that can be administered at low costs compared to traditional Alzheimer's medications. These compounds represent a cost-effective approach that addresses the root metabolic defect without requiring expensive complex drug regimens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TPK agonist effectively increases TDP levels, potentially reversing the metabolic disorder and providing a therapeutic or prophylactic benefit for neurodegenerative diseases, particularly Alzheimer's disease.
Implementation Method 1
The intracellular glucose metabolism process in AD patients is mainly characterized by a significant decrease in the activities of three key enzymes (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transketolase) that rely on thiamine diphosphate (TDP) as a coenzyme
Implementation Method 2
three key enzymes (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transketolase) that rely on thiamine diphosphate (TDP) as a coenzyme
Data Source
AI summary
The present disclosure belongs to the field of biomedicine, and specifically relates to a method for preventing or treating neurodegenerative diseases or alleviating symptoms of neurodegenerative diseases. Said method comprises administering an effective amount of a thiamine pyrophosphokinase (TPK) agonist to an individual in need of said agonist.